Different compounds were tested for their suitability, as a combination therapy with sorafenib, to overcome its lower efficacy treatment of advanced HCC, including bortezomib, rapamycin and a selective MEK inhibitor, AZD6244; the combined therapies had better responses compared to sorafenib11. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.